Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT01684878
First received: September 11, 2012
Last updated: July 5, 2016
Last verified: July 2016
  Purpose
This two-part, multicenter study will evaluate the safety, tolerability and efficacy of pertuzumab in combination with standard chemotherapy in women with recurrent platinum-resistant epithelial ovarian cancer. In the non-randomized Part 1 safety run-in, participants will receive pertuzumab plus either topotecan or paclitaxel. In the randomized, double-blind Part 2 of the study, participants will receive either pertuzumab or placebo in combination with chemotherapy (topotecan, paclitaxel, or gemcitabine).

Condition Intervention Phase
Ovarian Cancer
Drug: Gemcitabine (Chemotherapy)
Drug: Paclitaxel (Chemotherapy)
Drug: Pertuzumab
Drug: Placebo
Drug: Topotecan (Chemotherapy)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Two-Part, Randomized Phase III, Double-Blind, Multicenter Trial Assessing The Efficacy And Safety of Pertuzumab In Combination With Standard Chemotherapy Vs. Placebo Plus Standard Chemotherapy In Women With Recurrent Platinum-Resistant Epithelial Ovarian Cancer And Low HER3 mRNA Expression

Resource links provided by NLM:


Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Part 1: Percentage of Participants with Adverse Events [ Time Frame: Approximately 3.5 years (assessed at screening, baseline until 28 days after the last dose of study treatment) ] [ Designated as safety issue: No ]
  • Part 2: Progression Free Survival (PFS) as Assessed by a Blinded Independent Review Committee (IRC) Using Response Evaluation Criteria in Solid Tumors (RECIST) version (V) 1.1 [ Time Frame: Approximately 3.5 years (assessed at screening and every 9 weeks from randomization until disease progression) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • QoL Assessment Using EORCTC QLQ-Ovarian Cancer Module (OV) 28 Score [ Time Frame: Approximately 3.5 years (assessed at baseline and every 9 weeks from randomization until disease progression) ] [ Designated as safety issue: No ]
  • Functional Assessment of Cancer Therapy (FACT)/National Comprehensive Cancer Network (NCCN) Ovarian Symptom Index (FOSI) Total Score [ Time Frame: Approximately 3.5 years (assessed at baseline and every 9 weeks from randomization until disease progression) ] [ Designated as safety issue: No ]
  • QoL Assessment Using Three Worst Symptoms Questionnaires Score [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  • Part 2: Progression-free survival Assessed by the Investigator using RECIST V1.1 [ Time Frame: Approximately 3.5 years (assessed at screening and every 9 weeks from randomization until disease progression) ] [ Designated as safety issue: No ]
  • QoL Assessment Using Hospital Anxiety Depression Scale (HADS) Score [ Time Frame: Approximately 3.5 years (assessed at baseline and every 9 weeks from randomization until disease progression) ] [ Designated as safety issue: No ]
  • Part 1: PFS Assessed by the Investigator Using RECIST V1.1 [ Time Frame: Approximately 3.5 years (assessed at screening and every 9 weeks from randomization until disease progression) ] [ Designated as safety issue: No ]
  • Part 2: Overall Survival [ Time Frame: Approximately 3.5 years (assessed at screening, baseline, 28 days after the last dose of study treatment, 3 months post treatment follow-up) ] [ Designated as safety issue: No ]
  • Part 2: Percentage of Participants with an Objective Response of Complete Response (CR) or Partial Response (PR) According to RECIST V 1.1 [ Time Frame: Approximately 3.5 years (assessed at screening and every 9 weeks from randomization until disease progression) ] [ Designated as safety issue: No ]
  • Part 2: Percentage of Participants with Adverse Events [ Time Frame: Approximately 3.5 years (assessed at screening, baseline until 28 days after the last dose of study treatment) ] [ Designated as safety issue: No ]
  • Part 2: Quality of Life (QoL) - European Organization for Research and Treatment of Cancer (EORTC) QoL Questionnaire (QLQ) of Core 30 (C30) Score [ Time Frame: Approximately 3.5 years (assessed at baseline and every 9 weeks from randomization until disease progression) ] [ Designated as safety issue: No ]

Enrollment: 208
Study Start Date: October 2012
Study Completion Date: April 2016
Primary Completion Date: April 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Part 1: Pertuzumab + Paclitaxel
Participants will receive pertuzumab and paclitaxel in cycles of 3 weeks until progressive disease as per investigators assessment, unacceptable toxicity, withdrawal of consent, or death.
Drug: Paclitaxel (Chemotherapy)
Participants will be administered paclitaxel at a dosage of 80 milligrams per meter square (mg/m^2) as 1 hour IV infusion on Days 1, 8 and 15 every 3 weeks.
Drug: Pertuzumab
Participants will be administered pertuzumab 840 milligrams (mg) intravenous (IV) infusion on Day 1 of the first treatment cycle as a loading dose, followed by 420 mg on Day 1 of each subsequent 3 weekly cycle.
Drug: Placebo
Participants will be administered pertuzumab matching placebo IV infusion on Day 1 of each 3 weekly cycle.
Experimental: Part 1: Pertuzumab + Topotecan
Participants will receive pertuzumab and topotecan in cycles of 3 weeks until progressive disease as per investigators assessment, unacceptable toxicity, withdrawal of consent, or death.
Drug: Paclitaxel (Chemotherapy)
Participants will be administered paclitaxel at a dosage of 80 milligrams per meter square (mg/m^2) as 1 hour IV infusion on Days 1, 8 and 15 every 3 weeks.
Drug: Pertuzumab
Participants will be administered pertuzumab 840 milligrams (mg) intravenous (IV) infusion on Day 1 of the first treatment cycle as a loading dose, followed by 420 mg on Day 1 of each subsequent 3 weekly cycle.
Drug: Topotecan (Chemotherapy)
Participants will be administered topotecan at a dosage of 1.25 mg/m^2 as a 30 minute IV infusion daily on Days 1 to 5 every 3 weeks.
Experimental: Part 2: Pertuzumab+Chemotherapy
Participants will receive pertuzumab and chemotherapy (paclitaxel or topotecan or gemcitabine) in cycles of 3 weeks until progressive disease as per investigators assessment, unacceptable toxicity, withdrawal of consent, or death. The choice of chemotherapy will be at investigators discretion.
Drug: Gemcitabine (Chemotherapy)
Participants will be administered gemcitabine at a dosage of 1000 milligrams per square meter (mg/m^2) IV infusion on Days 1 and 8 every 3 weeks.
Drug: Paclitaxel (Chemotherapy)
Participants will be administered paclitaxel at a dosage of 80 milligrams per meter square (mg/m^2) as 1 hour IV infusion on Days 1, 8 and 15 every 3 weeks.
Drug: Pertuzumab
Participants will be administered pertuzumab 840 milligrams (mg) intravenous (IV) infusion on Day 1 of the first treatment cycle as a loading dose, followed by 420 mg on Day 1 of each subsequent 3 weekly cycle.
Drug: Topotecan (Chemotherapy)
Participants will be administered topotecan at a dosage of 1.25 mg/m^2 as a 30 minute IV infusion daily on Days 1 to 5 every 3 weeks.
Placebo Comparator: Part 2: Placebo+Chemotherapy
Participants will receive pertuzumab matching placebo and chemotherapy (paclitaxel or topotecan or gemcitabine) in cycles of 3 weeks until progressive disease as per investigators assessment, unacceptable toxicity, withdrawal of consent, or death. The choice of chemotherapy will be at investigators discretion.
Drug: Gemcitabine (Chemotherapy)
Participants will be administered gemcitabine at a dosage of 1000 milligrams per square meter (mg/m^2) IV infusion on Days 1 and 8 every 3 weeks.
Drug: Paclitaxel (Chemotherapy)
Participants will be administered paclitaxel at a dosage of 80 milligrams per meter square (mg/m^2) as 1 hour IV infusion on Days 1, 8 and 15 every 3 weeks.
Drug: Placebo
Participants will be administered pertuzumab matching placebo IV infusion on Day 1 of each 3 weekly cycle.
Drug: Topotecan (Chemotherapy)
Participants will be administered topotecan at a dosage of 1.25 mg/m^2 as a 30 minute IV infusion daily on Days 1 to 5 every 3 weeks.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed epithelial ovarian, primary peritoneal, and/or fallopian tube cancer that is platinum-resistant or refractory
  • Low Human epidermal growth factor receptor (HER) 3 messenger ribonucleic acid (mRNA) expression
  • At least one measurable and/or non-measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version (V) 1.1
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2
  • Left ventricular ejection fraction (LVEF) greater than or equal to (>/=) 50 percent (%)
  • Negative serum pregnancy test in women of childbearing potential
  • Women of childbearing potential must agree to use effective contraception as defined by protocol during and for at least 6 months post study treatment

Exclusion Criteria:

  • Non-epithelial tumors
  • Ovarian tumors with low malignant potential (borderline tumors)
  • History of other malignancy of prognostic relevance within the last 5 years, except for carcinoma in situ of the cervix or basal cell carcinoma, or tumors with a negligible risk for metastasis or death, such as adequately controlled basal-cell carcinoma or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or carcinoma in situ of the breast
  • Previous treatment with more than 2 chemotherapy regimens
  • Any prior radiotherapy to the pelvis or abdomen
  • History or evidence on physical/neurological examination of central nervous system disease unrelated to cancer (uncontrolled seizures), unless adequately treated with standard medical therapy
  • Pre-existing peripheral neuropathy >/= common toxicity criteria (CTC) grade 2 (applicable for paclitaxel cohort only)
  • Inadequate organ function
  • Uncontrolled hypertension or clinically significant cardiovascular disease
  • Current known infection with human immunodeficiency virus (HIV) or active infection with hepatitis B virus (HBV), or hepatitis C virus (HCV)
  • Current chronic daily treatment with corticosteroids (>/= 10 mg per day of methylprednisolone or equivalent), excluding inhaled steroids
  • History of receiving any investigational treatment within 28 days prior to first study drug administration
  • For Part 2 of the trial: prior enrollment into Part 1 of the trial
  • Concurrent participation in any therapeutic clinical trial
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01684878

  Show 68 Study Locations
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT01684878     History of Changes
Other Study ID Numbers: MO28113  2011-005975-17 
Study First Received: September 11, 2012
Last Updated: July 5, 2016
Health Authority: Spain: Health Authority Spain

Additional relevant MeSH terms:
Ovarian Neoplasms
Neoplasms, Glandular and Epithelial
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Neoplasms by Histologic Type
Paclitaxel
Gemcitabine
Pertuzumab
Albumin-Bound Paclitaxel
Topotecan
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antimetabolites
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents

ClinicalTrials.gov processed this record on September 23, 2016